Last updated: February 20, 2026
What is the drug associated with NDC 60505-3113?
NDC 60505-3113 corresponds to Aducanumab (brand name Aduhelm), a monoclonal antibody developed by Biogen for the treatment of Alzheimer’s disease. It was approved by the FDA on June 7, 2021, as the first therapy targeting amyloid plaques in the brain.
Market Overview
Market Size and Demand
The Alzheimer’s treatment market has expanded significantly, driven by an aging population and increasing prevalence. The global Alzheimer’s disease therapeutics market was valued at approximately $8 billion in 2022, with projections exceeding $12 billion by 2027 [1].
Competitive Landscape
Aducanumab’s approval marked a shift in Alzheimer’s treatment, competing mainly with:
- Lecanemab (Eisai/Biogen): Approved in 2023, showing comparable efficacy.
- Donanemab (Eli Lilly): Under review, potential competitor.
- Existing symptomatic therapies (e.g., cholinesterase inhibitors) have limited disease-modifying effects.
Adoption Factors
Prescription rates depend on:
- Physician acceptance
- Cost and insurance coverage
- Patient eligibility (e.g., early-stage Alzheimer’s)
- Monitoring and safety protocols
Pricing Analysis
Initial Contracted Price
Biogen initially set Aduhelm at $56,000 annually per patient. This price sparked controversy, prompting payers to scrutinize reimbursement and coverage policies.
Reimbursement and Coverage Dynamics
Medicare announced coverage limitations for Aduhelm, restricting use to clinical trial settings or certain paid pathways, which will constrain market penetration.
Price Trends and Projections
Given the initial high price and reimbursement restrictions, actual market penetration remains limited. Price compression is likely as competition and payer negotiations intensify. For modeling purposes:
| Year |
Estimated Price per Patient |
Notes |
| 2023 |
$56,000 |
Initial pricing, limited coverage |
| 2024 |
$35,000 - $45,000 |
Payer negotiations, expanded clinical use potential |
| 2025+ |
$25,000 - $35,000 |
Competitive pricing as biosimilars/competitors gain market share |
Cost-Effectiveness and Pricing Impacts
Healthcare payers are evaluating Aduhelm’s cost-effectiveness, given its modest efficacy and high cost. Future price adjustments will depend on clinical real-world data, safety profiles, and negotiated discounts.
Market Penetration Forecast
Investment in Clinical & Commercial Infrastructure
Biogen and partners have invested in:
- Neurology clinics
- Patient monitoring programs
- Physician education initiatives
This infrastructure will support increased uptake in subsequent years but is challenged by safety concerns and reimbursement barriers.
Adoption Curve
Estimative patient uptake:
| Year |
Patients Treated |
Notes |
| 2022 |
<10,000 |
Limited due to formulary restrictions |
| 2023 |
15,000 – 25,000 |
Gradual adoption, initial coverage |
| 2024 |
50,000 – 70,000 |
Broader prescriber acceptance |
| 2025+ |
100,000+ |
Potential acceleration in uptake |
Regulatory & Policy Impact
- FDA Approval: Conditional, with current controversy around efficacy.
- Medicare Coverage: Limited, influencing market size.
- Reimbursement Negotiations: Key driver in price adjustments.
Summary
- The initial market for Aduhelm is constrained by high pricing and insurance limitations.
- Prices are expected to decline significantly as payers negotiate discounts and competition increases.
- Market penetration will be driven by prescriber acceptance, safety data, and reimbursement policies.
- Long-term price projections for 2024 and beyond range between $25,000 and $45,000 annually per patient.
Key Takeaways
- Aduhelm started at $56,000 annually but faces downward pressure due to reimbursement restrictions.
- Market penetration remains limited; full-scale adoption depends on policy, safety, and efficacy data.
- Competition from Lecanemab and other emerging therapies will influence pricing and market share.
- Payer negotiations will be pivotal in shaping future pricing trends.
- The Alzheimer’s therapeutics market has growth potential, but high costs and regulatory challenges persist.
FAQs
1. How does Aduhelm compare to other Alzheimer’s therapies?
Aduhelm is the first disease-modifying therapy targeting amyloid plaques; earlier treatments primarily focused on symptomatic relief.
2. What factors influence the price of Aduhelm?
Market demand, reimbursement policies, competition, and negotiated discounts primarily determine the price.
3. How will reimbursement policies impact market growth?
Restrictions from Medicare and payers limit initial adoption; expanded coverage could increase market penetration.
4. Are biosimilars or generics expected for Aduhelm?
Biosimilars are unlikely soon due to complex manufacturing. Competition will mainly come from new therapeutic agents.
5. What is the long-term outlook for Aduhelm pricing?
Prices are expected to decline with wider adoption, increased competition, and value-based reimbursement models.
References
[1] MarketResearch.com. (2022). Alzheimer’s Disease Therapeutics Market Analysis.
